EAU 2016 - Prostate Cancer

REVIEW UroToday

Viewing 1-20 of 30 articles

EAU 2016: Degarelix is well tolerated and effective for the treatment of prostate cancer: Results from a phase III study in China - Poster

EAU 2016 Pathologic outcomes using different extended templates for lymph node dissection at radical prostatectomy - Poster Session Highlights

EAU 2016 Radium-223 (Ra-223) re-treatment (re-tx): Experience from an international, multicenter, prospective study in patients (pts) with castration-resistant prostate cancer and bone metastases (mCRPC) - Poster Session Highlights

EAU 2016 Survival Outcomes in Octogenarian and nonagenarian patients treated with first-line androgen deprivation therapy for localized prostate cancer. - Session Highlights

EAU 2016 Long-term quality of life outcomes after active surveillance or curative treatment for prostate cancer - Session Highlights

EAU 2016 Comparative analysis of immediate vs delayed prostatectomy in prostate cancer patients eligible for active surveillance. - Session Highlights

EAU 2016 Phase III intermittent vs continuous ADT - Poster Session Highlights

EAU 2016 Immunotherapy for prostate cancer: What the future holds - Session Highlights

EAU 2016 Prostate Cancer—Management of atypical histologies - Session Highlights

EAU 2016 Greater Survival Benefit Shown in Men with Early and Less Aggressive Metastatic Castration-Resistant Prostate Cancer Treated with ZYTIGA® Plus Prednisone

EAU 2016 How to optimise the use of imaging in the recurrent setting: The role of PET/CT - Session Highlights

EAU 2016 State-of-the-art lecture: The genomic picture of recurrent prostate cancer - Session Highlights

EAU 2016 State-of-the-art lecture: Long term quality of life in survivors - Session Highlights

EAU 2016 Debate - Timing of radiotherapy after radical prostatectomy - Session Highlights

EAU 2016 State-of-the-art lecture: Prevention and management of biopsy complications - Session Highlights

EAU 2016 Debate - Is there a role for pre-biopsy MRI? - Session Highlights

EAU 2016 Debate—Timing of radiotherapy after radical prostatectomy: Pro Adjuvant therapy - Session Highlights

EAU 2016 Plenary Session Debate Discussant: Is there a role for pre-biopsy MRI for prostate cancer diagnosis? - Session Highlights

EAU 2016 Plenary Session State-of-the-art lecture: Is genomics going to help us find high-risk disease? - Session Highlights

EAU 2016 National trends and differences in morbidity among surgical approaches for radical prostatectomy in Germany - Poster Session Highlights

1
2